Archive · 2 Oct 2026
RML Recalls Drug Batches After Quality Checks Flag Defects
RML checked some medicines for quality.
Three tablet batches did not pass the tests.
They were sodium valproate, spironolactone and imipramine tablets.
Five injectable medicines also failed their tests.
These included adenosine, methyl ergometrine and multivitamin injection.
They also included pheniramine maleate and ascorbic acid.
The medicines were labelled “Not of Standard Quality” or recalled.
The headline says 10 batches, but the details list eight batches in total.
RML’s final notice was dated September 14.
Three tablet batches failed analytical testing and were labelled “Not of Standard Quality.”
The affected tablets were sodium valproate 200mg, spironolactone 50mg and imipramine 25mg.
RML’s injectable drug unit recalled five batches after they also failed analytical testing.
The injectable medicines were adenosine, methyl ergometrine, multivitamin injection, pheniramine maleate and ascorbic acid.
- Who
- RML’s oral and topical drug unit and injectable drug unit.
- What
- Three tablet batches were labelled “Not of Standard Quality,” and five injectable medicine batches were urgently recalled.
- When
- September 14.
- Where
- At RML’s oral and topical drug unit and injectable drug unit.
- Why
- The batches failed analytical testing during quality checks.
- Notice date
- September 14
- Tablet batches affected
- 3
- Injectable batches affected
- 5
- Total batches detailed
- 8
- Tablet medicines
- Sodium valproate gastro-resistant 200mg, spironolactone 50mg and imipramine 25mg
- Injectable medicines
- Adenosine, methyl ergometrine, multivitamin injection, pheniramine maleate and ascorbic acid
- Reported discrepancy
- The headline refers to 10 batches, while the article details identify eight